2022 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人尹辉、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | 109,129.93 | 30,343.03 | | | 越权审批，或无正式批准文件，或偶发性的税收返还、 | | | | | 减免 | | | | | 计入当期损益的政府补助，但与公司正常经营业务密切 | | | | | 相 ...

2022 年半年度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2022 年半年度报告 1 / 159 2022 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述公司可能面临的风险，敬请投资者予以关注，具体详见本报告第 三节管理层讨论与分析之五、（一）可能面对的风险。 十一、 其他 □适用 √不适用 2 / 159 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 ...

证券代码：600222 证券简称：太龙药业 编号：临 2022-036 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2022 年 5 月 30 日（周一）15:30-17:00 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2022 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长尹辉先生、 总经理罗剑超先生、董事会秘书冯海燕女士、财务负责人赵海林先生 （如有特殊情况，参会人员将可能进行调整），欢迎广大投资者积极 参与。 特此公告。 河南太龙药业股份有限公司董事会 2022 年 5 月 26 日 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 422,282,414.89, representing a year-on-year increase of 1.52%[5] - The net profit attributable to shareholders of the listed company was CNY 2,329,695.73, showing a significant decrease of 91.33% compared to the same period last year[5] - The basic earnings per share (EPS) was CNY 0.0041, down 91.48% year-on-year[6] - Total revenue for Q1 2022 was CNY 422,282,414.89, a slight increase of 0.78% compared to CNY 415,958,437.10 in Q1 2021[22] - Net profit for Q1 2022 was CNY 2,166,570.19, a significant decrease of 91.86% from CNY 26,632,438.79 in Q1 2021[23] - The company's operating profit for Q1 2022 was CNY 2,976,218.24, down from CNY 30,641,135.93 in Q1 2021, indicating a decline of 90.31%[23] - Basic and diluted earnings per share for Q1 2022 were CNY 0.0041, down from CNY 0.0481 in Q1 2021, a decline of 91.49%[24] - Other comprehensive income for Q1 2022 was negative CNY 4,641,036.70, contrasting with a positive CNY 196,461,366.30 in Q1 2021[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,789,529,131.70, a slight increase of 0.15% from the end of the previous year[6] - The total assets as of Q1 2022 amounted to CNY 3,789,529,131.70, slightly up from CNY 3,783,772,407.22 at the end of Q1 2021[21] - Total liabilities for Q1 2022 were CNY 1,884,367,020.68, down from CNY 2,006,135,829.69 in Q1 2021, a decrease of 6.09%[21] - The company's total equity increased to CNY 1,905,162,111.02 in Q1 2022, compared to CNY 1,777,636,577.53 in Q1 2021, marking an increase of 7.16%[21] Cash Flow - The net cash flow from operating activities was negative at CNY -151,971,688.24, indicating a significant cash outflow[5] - Cash inflow from operating activities for Q1 2022 was $363.89 million, up from $312.19 million in Q1 2021, representing a 16.5% increase[26] - Net cash outflow from operating activities for Q1 2022 was -$151.97 million, compared to -$43.52 million in Q1 2021, indicating a significant decline[27] - Cash inflow from investment activities for Q1 2022 was $591.64 million, a substantial increase from $162.82 million in Q1 2021, marking a 263.5% rise[27] - Cash inflow from financing activities for Q1 2022 was $102.20 million, down from $165.15 million in Q1 2021, showing a decrease of 38.1%[27] - The ending cash and cash equivalents balance for Q1 2022 was $214.11 million, down from $493.69 million in Q1 2021, indicating a decline of 56.7%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,264[10] - The company’s major shareholder changed to Zhengzhou Tai Rong Industrial Investment Co., Ltd., which acquired 82,441,168 shares, accounting for 14.37% of the total share capital[13] - The company’s board of directors and supervisory board were restructured on February 25, 2022, with a new chairman elected[13] - The company’s repurchase account held 10,846,107 shares, representing 1.89% of the total shares as of the reporting period[12] Expenses and Investments - The decline in net profit was primarily due to the sales restrictions on four categories of drugs, leading to decreased revenue and gross profit[8] - The company faced increased sales expenses as it intensified market promotion for other product lines[8] - Research and development expenses increased to CNY 19,581,712.93 in Q1 2022, compared to CNY 14,409,179.35 in Q1 2021, reflecting a growth of 36.06%[23] - Non-recurring gains and losses amounted to a net loss of CNY -120,616.38 after tax adjustments[8] - The company received financial support of up to 1.2 billion RMB from its indirect controlling shareholder, with the first tranche of 419 million RMB already received[15] - The company’s long-term equity investments stood at 15,473,270.37 RMB as of March 31, 2022, slightly down from 15,724,611.04 RMB at the end of 2021[17] - The company’s total liabilities and equity structure will be impacted by the recent changes in major shareholders and financial support arrangements[13][15]

Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of RMB 5,995,375.55, a decrease of 79.50% compared to RMB 29,240,862.39 in 2020[5]. - The company's operating revenue for 2021 was RMB 1,604,516,940.00, representing a year-on-year increase of 13.23% from RMB 1,417,097,311.59 in 2020[21]. - The net cash flow from operating activities increased by 35.72% to RMB 99,655,159.11 in 2021, compared to RMB 73,427,546.30 in 2020[21]. - The total assets of the company as of the end of 2021 were RMB 3,783,772,407.22, an increase of 11.64% from RMB 3,389,394,715.08 at the end of 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 36,179,012.56, a significant increase of 159.11% compared to RMB 13,962,693.07 in 2020[21]. - Basic earnings per share (EPS) fell by 80.00% to RMB 0.0107, while diluted EPS remained the same[22]. - The weighted average return on equity (ROE) decreased by 1.73 percentage points to 0.37%[22]. - The company reported a significant loss of RMB 30.18 million from non-recurring gains and losses, impacting overall profitability[27]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.10 per share, totaling RMB 5,630,401.76, which accounts for 93.91% of the net profit attributable to shareholders for 2021[5]. - For the 2021 fiscal year, the company plans to distribute a cash dividend of CNY 0.10 per share (including tax), amounting to CNY 5,630,401.76, which represents 93.91% of the net profit attributable to shareholders of the parent company[172]. Business Growth and Strategy - The company's operating revenue increased by 13.23% year-on-year, driven by a 35.74% growth in pharmaceutical R&D services and a 19.31% increase in traditional Chinese medicine products[23]. - The company is focusing on expanding its market presence and enhancing brand promotion for its traditional Chinese medicine products[23]. - The company is actively expanding its market presence by integrating existing traditional Chinese medicine products and increasing marketing investments in targeted product combinations[34]. - The company aims to enhance product quality through strict adherence to production standards and quality management practices[49]. - The company is committed to expanding its market presence and enhancing brand influence through strategic partnerships and marketing initiatives[56]. Research and Development - The company has 906 personnel in the R&D team, with 23.62% holding master's or doctoral degrees, indicating a strong talent pool[36]. - The company has established multiple platforms for drug research, focusing on high-end formulations and innovative drug research, including preclinical and clinical trial services[57]. - The company has initiated 56 new research projects in high-end generic and innovative drugs, bringing the total number of ongoing projects to 267[103]. - The company is focusing on high-barrier therapeutic areas such as cardiovascular, anti-tumor, and digestive system drugs, aligning R&D efforts with market demand[103]. - The company is conducting clinical research on TLZ0005, a new drug for breast disease, which is currently in the clinical research phase[104]. Environmental Responsibility - The company was listed as a key pollutant discharge unit in Zhengzhou for 2021, with strict adherence to national standards for pollutant treatment and discharge[184]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties from environmental protection authorities[185]. - The company has implemented a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutants are within regulatory limits[192]. - The company emphasizes a low-carbon production philosophy, advocating for resource conservation and green practices among employees[197]. Governance and Management - The governance structure of the company is robust, ensuring compliance with laws and regulations while protecting shareholder interests[134]. - The company maintains transparent communication with investors, ensuring their rights are protected and fostering good investor relations[136]. - The company completed the election of the ninth board of directors and the ninth supervisory board on February 25, 2022, with new appointments including Yin Hui as chairman and Luo Jianchao as general manager[143]. - The company has proposed to allocate profits for the year 2020, indicating a focus on shareholder returns[139]. - The company has established a comprehensive human resources management system, including salary and welfare, performance evaluation, training management, and promotion systems[169]. Market Trends and Industry Insights - The Chinese CRO market is expected to grow at a compound annual growth rate (CAGR) of 20.22% from 2020 to 2030, reaching a market size of approximately 329.2 billion yuan by 2030[42]. - The global CRO market is projected to reach $168.9 billion by 2030, with a CAGR of 9.95% from 2020 to 2030[42]. - The pharmaceutical manufacturing industry achieved operating revenue of 2,928.85 billion yuan in 2021, growing by 20.1% year-on-year, indicating a robust industry trend[40]. - The ongoing reforms in the medical insurance system are expected to further support the development of TCM services and products[47]. Community Engagement - The company donated over 1.5 million yuan worth of medicines to support disaster relief efforts following severe flooding[198]. - The company aims to support rural economic development by promoting standardized planting techniques and processing projects for traditional Chinese medicine[199].

2021 年第三季度报告 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李景亮、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡 志权保证季度报告中财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减变 | | --- | --- | --- | --- | --- | | | | | | 动幅度(%) | | | | 调整前 | 调整后 | 调整后 | | 总资产 | 3,857,651,202.83 | 3,389,394,715.08 | 3,389,394,715.08 | 13.82 | | 归属于上市公司股 东的所有者权益 | 1,621,63 ...

2021 年半年度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2021 年半年度报告 1 / 162 2021 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述公司可能面临的风险，敬请投资者予以关注，详见本报告第三节 管理层讨论与分析之五、（一）可能面对的风险。 十一、 其他 □适用 √不适用 2 / 162 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人 ...

证券代码：600222 证券简称：太龙药业 编号：临 2021-029 河南太龙药业股份有限公司 关于参加河南辖区上市公司 2021 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强投资者的互动交流，河南太龙药业股份有限公司定 于 2021 年 6 月 8 号（周二）16:00-17:20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待日 活动，本次活动将采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事兼总经理罗剑 超先生、董事会秘书冯海燕女士（如有特殊情况，参会人员将可能进 行调整），欢迎广大投资者积极参与。 特此公告。 河南太龙药业股份有限公司董事会 2021 年 6 月 4 日 ...

2021 年第一季度报告 公司代码：600222 公司简称：太龙药业 河南太龙药业股份有限公司 2021 年第一季度报告 1 / 25 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李景亮、主管会计工作负责人赵海林及会计机构负责人（会计主管人员）胡志权 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | | | | 增减(%) | | | 总资产 | 3,739,251,867.46 | 3 ...

Financial Performance - In 2020, the company achieved a net profit attributable to shareholders of 29,240,862.39 CNY, a decrease of 34.16% compared to the previous year[5]. - The total operating revenue for 2020 was 1,417,097,311.59 CNY, representing an increase of 8.03% from 2019[25]. - The company reported a significant decline in net profit compared to 2019, which was 44,414,622.07 CNY[25]. - The company's net profit attributable to shareholders decreased by 34.16% year-on-year, primarily due to increased raw material costs and fixed expenses during the pandemic[28]. - Basic earnings per share decreased by 33.04% to RMB 0.0535, reflecting the overall decline in profitability[27]. - The weighted average return on equity fell to 2.10%, a decrease of 1.08 percentage points compared to the previous year[27]. - The company reported a total revenue of 15,278,169.32, with a year-on-year increase of 5,772,488.18[35]. - The company achieved operating revenue of 1,417.10 million yuan in 2020, representing a year-on-year growth of 8.03%[62]. - The net profit attributable to shareholders was 29,240,900 CNY, with a net profit of 13,962,700 CNY after deducting non-recurring gains and losses[62]. Cash Flow and Dividends - The cash dividend proposed is 0.16 CNY per share, totaling 9,008,642.82 CNY, which accounts for 30.81% of the net profit attributable to shareholders[5]. - As of December 31, 2020, the profit available for distribution to shareholders was 184,253,477.46 CNY[5]. - Operating cash flow increased by 76.82% year-on-year, attributed to a higher proportion of cash collections during the reporting period[29]. - The company reported a significant increase in net cash flow from operating activities, amounting to 73,427,546.30 CNY, a 76.82% increase compared to the previous year[64]. - Net cash inflow from financing activities was 209.57 million yuan, a significant increase of 211.48% year-on-year, driven by increased bank financing and capital contributions[83]. Investments and Acquisitions - The company acquired a 33.95% stake in Tailong Health, increasing its ownership to 80.40%, allowing for control over the entity[27]. - The company increased its investment in the healthcare sector, acquiring control of Tailong Health Industry Investment Co., Ltd., and established two funds with a fair value increase of 24.6 million CNY during the reporting period[60]. - The company completed a capital increase of RMB 130 million from Jinggang Fund, acquiring a 20% stake in Shenlanhai[157]. - The company acquired 33.95% equity of Tailong Health from its controlling shareholder for RMB 127.9 million during the reporting period[157]. Revenue by Segment - Revenue from traditional Chinese medicine oral liquid products increased by 35.88% year-on-year, driven by market demand during the pandemic[28]. - The pharmaceutical formulation business generated revenue of 478.93 million yuan, with a year-on-year increase of 32.76%[56]. - The revenue from the clinical CRO services segment was 238.79 million yuan, reflecting a year-on-year growth of 6.45%[59]. - Revenue from traditional Chinese medicine pieces decreased by 4.00% year-on-year, with a gross margin decline of 18.69 percentage points[70]. - Pharmaceutical distribution revenue fell by 31.29% year-on-year, primarily due to the company's strategic adjustment to reduce drug distribution operations[70]. - Revenue from herbal medicine trading increased by 31.50% year-on-year, driven by growth in orders for high-quality ecological medicinal materials[70]. Research and Development - The company aims to enhance its drug research and development services, focusing on reducing risks and shortening development cycles for clients[37]. - The company’s R&D services cover the entire pharmaceutical development chain, including preclinical research and clinical CRO services, aimed at maximizing client returns by reducing time and cost[41]. - R&D expenses rose by 7.21% to 63,664,588.06 CNY, reflecting the company's commitment to innovation[64]. - The company has over 80 ongoing R&D projects, primarily in cardiovascular, anti-tumor, and digestive system areas, including clinical trials for new drugs[107]. - R&D investment for the reporting period accounted for 4.50% of total revenue, with a year-on-year increase of 7.13% in R&D spending[112]. Corporate Governance and Compliance - The company has committed to reducing and regulating related party transactions with its controlling shareholders to avoid conflicts of interest[144]. - The controlling shareholder promised not to engage in any competitive business activities within China that could harm the company's interests[144]. - The company is focused on ensuring compliance with legal and regulatory requirements in all related party transactions[144]. - The company aims to maintain transparency and fairness in its dealings with related parties to protect shareholder interests[144]. - The company has implemented the new revenue recognition standards since January 1, 2020, which did not have a significant impact on its financial position and operating results[147]. Environmental Responsibility - The company reported that the concentrations and total emissions of SO2 and nitrogen oxides from both production sites were below the approved discharge limits[179]. - The company has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[173]. - The wastewater treatment facility has a daily processing capacity of 1,000 tons, and the treatment process includes multiple stages to ensure compliance with discharge standards[177]. - The company has implemented a self-monitoring scheme for environmental compliance, with third-party monitoring showing all pollutants meet discharge standards[182]. Shareholder Information - The total number of ordinary shares after the recent changes is 573,886,283, with 99.39% being freely tradable[187]. - The company completed a non-public issuance of A-shares totaling 77,277,371 shares, increasing the total share capital from 496,608,912 shares to 573,886,283 shares[188]. - The total number of ordinary shareholders increased from 45,174 to 50,196, representing a growth of approximately 11.3%[191]. - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 132,441,168 shares, accounting for 23.08% of the total shares[194]. Social Responsibility - The company donated 6 million RMB worth of medicines to medical and public welfare institutions in response to the COVID-19 pandemic[171]. - The company has established long-term stable Chinese medicinal material supply bases to support local farmers, contributing to poverty alleviation efforts[167]. - The company reported a total of 37.14 million RMB invested in poverty alleviation initiatives during the reporting period[168].